Jan 15, 2021
Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering
Nov 30, 2020
Titan Pharmaceuticals Announces Reverse Stock Split
Nov 16, 2020
Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results
Nov 02, 2020
Titan Pharmaceuticals Completes Debt Settlement With Molteni And Horizon & Acquisiton Of JT Pharma's Kappa Opioid Agonist Peptide, JT-09
Oct 28, 2020
Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
Oct 26, 2020
Titan Pharmaceuticals Announces Debt Settlement Agreement with Molteni and Horizon
Oct 15, 2020
Titan Pharmaceuticals Provides a Strategic & Corporate Update
Sep 24, 2020
Titan Pharmaceuticals Announces Pricing of $2.7 Million Registered Direct Offering
Sep 18, 2020
Titan Pharmaceuticals' Stockholders Approve Proposal To Amend Its Certificate Of Incorporation
Sep 14, 2020
Titan Pharmaceuticals Provides Update To Stockholders On Proposal To Amend Its Certificate Of Incorporation
Aug 14, 2020
Titan Pharmaceuticals Reports Second Quarter 2020 Financial Results
Aug 10, 2020
Titan Pharmaceuticals To Report Second Quarter 2020 Financial Results On August 14, 2020
Jul 08, 2020
Titan Pharmaceuticals Urges Stockholders to Vote "FOR" Proposal to Amend Its Certificate of Incorporation
Jun 24, 2020
Titan Pharmaceuticals And Indegene Enter Into Probuphine® Co-Promotion Partnership
May 15, 2020
Titan Pharmaceuticals Reports First Quarter 2020 Financial Results
May 11, 2020
Titan Pharmaceuticals To Report First Quarter 2020 Financial Results On May 15, 2020
Mar 26, 2020
Titan Pharmaceuticals To Report Fourth Quarter And Full Year 2019 Financial Results On March 30, 2020
Mar 05, 2020
Titan Pharmaceuticals Receives $5.9 Million From Exercise Of Warrants
Jan 13, 2020
Titan Pharmaceuticals Announces Addition Of Probuphine® To Federal Supply Schedule
Jan 07, 2020
Titan Pharmaceuticals Announces Pricing of $2.2 Million Registered Direct Offering